Literature DB >> 24251413

Does uncoupling protein 2 expression qualify as marker of disease status in LRRK2-associated Parkinson's disease?

Anne Grünewald1, Björn Arns, Britta Meier, Kathrin Brockmann, Vera Tadic, Christine Klein.   

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common known genetic cause of late-onset Parkinson's disease (PD). However, the penetrance of the disease is below 50% at 60 years of age. LRRK2 is associated with the mitochondrial membrane, and mutant forms impair the function of the organelle and autophagosome clearance in human cells, including induced pluripotent stem cell-derived neurons. Elevated expression of uncoupling proteins has been identified as the cause of mitochondrial depolarization in human fibroblasts with G2019S LRRK2. To identify factors that contribute to the penetrance of LRRK2 mutations, we studied respiratory chain function, markers of mitochondrial uncoupling, oxidative stress, and autophagy in fibroblasts from affected and unaffected carriers of the G2019S mutation. Independent of disease status, all mutation carriers showed reduced mitochondrial membrane potential, increased proton leakage, and more fragmented mitochondria. However, a significant increase in the expression of uncoupling protein 2 (UCP2) was only detected in affected individuals with the G2019S mutation in LRRK2. Since oxidative stress and autophagic markers were selectively increased in some of the PD patients, we hypothesize that UCP2 expression is upregulated in response to elevated reactive oxygen species generation in affected mutation carriers and that UCP2 mRNA levels might, therefore, serve as markers of disease status in LRRK2-associated PD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24251413      PMCID: PMC3993019          DOI: 10.1089/ars.2013.5737

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  9 in total

Review 1.  The biology of mitochondrial uncoupling proteins.

Authors:  Sophie Rousset; Marie-Clotilde Alves-Guerra; Julien Mozo; Bruno Miroux; Anne-Marie Cassard-Doulcier; Frédéric Bouillaud; Daniel Ricquier
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

2.  LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.

Authors:  Ha Nam Nguyen; Blake Byers; Branden Cord; Aleksandr Shcheglovitov; James Byrne; Prachi Gujar; Kehkooi Kee; Birgitt Schüle; Ricardo E Dolmetsch; William Langston; Theo D Palmer; Renee Reijo Pera
Journal:  Cell Stem Cell       Date:  2011-03-04       Impact factor: 24.633

3.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

Authors:  John R Adams; Hinke van Netten; Michael Schulzer; Edwin Mak; Jessamyn Mckenzie; Audrey Strongosky; Vesna Sossi; Thomas J Ruth; Chong S Lee; Matthew Farrer; Thomas Gasser; Ryan J Uitti; Donald B Calne; Zbigniew K Wszolek; A Jon Stoessl
Journal:  Brain       Date:  2005-08-04       Impact factor: 13.501

4.  Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2.

Authors:  Heather Mortiboys; Krisztina K Johansen; Jan O Aasly; Oliver Bandmann
Journal:  Neurology       Date:  2010-11-30       Impact factor: 9.910

Review 5.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Nat Rev Neurosci       Date:  2010-11-19       Impact factor: 34.870

6.  PINK1-dependent recruitment of Parkin to mitochondria in mitophagy.

Authors:  Cristofol Vives-Bauza; Chun Zhou; Yong Huang; Mei Cui; Rosa L A de Vries; Jiho Kim; Jessica May; Maja Aleksandra Tocilescu; Wencheng Liu; Han Seok Ko; Jordi Magrané; Darren J Moore; Valina L Dawson; Regis Grailhe; Ted M Dawson; Chenjian Li; Kim Tieu; Serge Przedborski
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

7.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Authors:  Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood
Journal:  Lancet Neurol       Date:  2008-06-06       Impact factor: 44.182

8.  Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.

Authors:  Adriana Sánchez-Danés; Yvonne Richaud-Patin; Iria Carballo-Carbajal; Senda Jiménez-Delgado; Carles Caig; Sergio Mora; Claudia Di Guglielmo; Mario Ezquerra; Bindiben Patel; Albert Giralt; Josep M Canals; Maurizio Memo; Jordi Alberch; José López-Barneo; Miquel Vila; Ana Maria Cuervo; Eduard Tolosa; Antonella Consiglio; Angel Raya
Journal:  EMBO Mol Med       Date:  2012-03-08       Impact factor: 12.137

9.  G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.

Authors:  Tatiana D Papkovskaia; Kai-Yin Chau; Francisco Inesta-Vaquera; Dmitri B Papkovsky; Daniel G Healy; Koji Nishio; James Staddon; Michael R Duchen; John Hardy; Anthony H V Schapira; J Mark Cooper
Journal:  Hum Mol Genet       Date:  2012-06-26       Impact factor: 6.150

  9 in total
  14 in total

1.  Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.

Authors:  Joanna A Korecka; Ria Thomas; Dan P Christensen; Anthony J Hinrich; Eliza J Ferrari; Simon A Levy; Michelle L Hastings; Penelope J Hallett; Ole Isacson
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

Review 2.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

3.  LRRK2 and mitochondria: Recent advances and current views.

Authors:  Alpana Singh; Lianteng Zhi; Hui Zhang
Journal:  Brain Res       Date:  2018-06-09       Impact factor: 3.252

Review 4.  Aberrant autophagy and parkinsonism: does correction rescue from disease progression?

Authors:  Abhishek Kumar Mishra; Mohd Sami ur Rasheed; Saurabh Shukla; Manish Kumar Tripathi; Anubhuti Dixit; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2014-05-16       Impact factor: 5.590

5.  Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.

Authors:  G A Smith; J Jansson; E M Rocha; T Osborn; P J Hallett; O Isacson
Journal:  Mol Neurobiol       Date:  2015-09-23       Impact factor: 5.590

6.  Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2 G2019S -Parkinson's disease.

Authors:  Diana Luz Juárez-Flores; Ingrid González-Casacuberta; Mario Ezquerra; María Bañó; Francesc Carmona-Pontaque; Marc Catalán-García; Mariona Guitart-Mampel; Juan José Rivero; Ester Tobias; Jose Cesar Milisenda; Eduard Tolosa; Maria Jose Marti; Ruben Fernández-Santiago; Francesc Cardellach; Constanza Morén; Glòria Garrabou
Journal:  J Transl Med       Date:  2018-06-08       Impact factor: 5.531

Review 7.  Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows.

Authors:  Helena Xicoy; Núria Peñuelas; Miquel Vila; Ariadna Laguna
Journal:  Cells       Date:  2019-10-25       Impact factor: 6.600

8.  UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo.

Authors:  Heather Mortiboys; Rebecca Furmston; Gunnar Bronstad; Jan Aasly; Chris Elliott; Oliver Bandmann
Journal:  Neurology       Date:  2015-08-07       Impact factor: 9.910

Review 9.  From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2.

Authors:  Andrea Mancini; Petra Mazzocchetti; Miriam Sciaccaluga; Alfredo Megaro; Laura Bellingacci; Dayne A Beccano-Kelly; Massimiliano Di Filippo; Alessandro Tozzi; Paolo Calabresi
Journal:  Front Cell Neurosci       Date:  2020-07-28       Impact factor: 5.505

10.  Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease.

Authors:  Barbara Calamini; Nathalie Geyer; Nathalie Huss-Braun; Annie Bernhardt; Véronique Harsany; Pierrick Rival; May Cindhuchao; Dietmar Hoffmann; Sabine Gratzer
Journal:  Dis Model Mech       Date:  2021-06-11       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.